Unibest

Pharmaceutical intermediates

Lasmiditan Intermediates

1 pharmaceutical intermediate for Lasmiditan. Indication: Migraine.

提交项目All intermediates

About Lasmiditan

Originator
Eli Lilly
Indication
Migraine
Approved Date
12/18/2020
NCE Patent
01/31/2025
DS/DP
02/17/2028

Available intermediates

1 intermediate currently listed for Lasmiditan. Request specifications, documentation or a quotation for any item below.

Lasmiditan intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2,4,6-Trifluorobenzoic acid28314-80-9//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLazertinib MesylateLemborexantLenacapavir sodiumLenalidomide

Building toward Lasmiditan?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →